# Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors

> **NCT02700568** · PHASE2 · COMPLETED · sponsor: **Kidney Cancer Research Bureau** · enrollment: 21 (actual)

## Conditions studied

- Carcinoma, Renal Cell
- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** axitinib

## Key facts

- **NCT ID:** NCT02700568
- **Lead sponsor:** Kidney Cancer Research Bureau
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2018-06
- **Final completion:** 2018-08
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2019-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02700568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02700568, "Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02700568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*